You are here: Home: CCU 1 | 2003: Niall Tebbutt, BM, Bch, PhD, MRCP, FRCP: Select publications

Select publications of clinical trial results in advanced esophagogastric cancer

Aitini E et al. Epirubicin, cisplatin and continuous infusion 5-fluorouracil (ECF) in locally advanced or metastatic gastric cancer: A single institution experience. Tumori 2001;87(1):20-4. Abstract

Ajani JA et al. Irinotecan/cisplatin in advanced, treated gastric or gastroesophageal junction carcinoma. Oncology (Huntingt) 2002;16(5 Suppl 5):16-8. Abstract

Ajani JA et al. A three-step strategy of induction chemotherapy then chemoradiation followed by surgery in patients with potentially resectable carcinoma of the esophagus or gastroesophageal junction. Cancer 2001;92(2):279-86. Abstract

Blanke CD et al. A phase II study of irinotecan with 5-fluorouracil and leucovorin in patients with previously untreated gastric adenocarcinoma. Ann Oncol 2001;12(11):1575-80. Abstract

Cho EK et al. Epirubicin, cisplatin, and protracted venous infusion of 5-fluorouracil for advanced gastric carcinoma. J Korean Med Sci 2002;17(3):348-52. Abstract

Cullingford G et al. A phase II feasibility study of pre-operative & post-operative chemotherapy (epirubicin, cisplatin & 5FU (ECF)) in patients with advanced but operable gastric cancer: An Australasian Gastro-Intestinal Trials Group (AGITG) study (AG9601). Proc ASCO 2002; Abstract 695.

Dallal HJ et al. A randomized trial of thermal ablative therapy versus expandable metal stents in the palliative treatment of patients with esophageal carcinoma. Gastrointest Endosc 2001;54(5):549-57. Abstract

Macdonald JS et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001;345(10):725-30. Abstract

Polee MB et al. Phase II study of bi-weekly administration of paclitaxel and cisplatin in patients with advanced oesophageal cancer. Br J Cancer 2002;86(5):669-73. Abstract

Ross P et al. Prospective randomized trial comparing mitomycin, cisplatin, and protracted venousinfusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol 2002;20(8):1996-2004. Abstract

Schnirer II et al. Pilot study of concurrent 5-fluorouracil/paclitaxel plus radiotherapy in patients with carcinoma of the esophagus and gastroesophageal junction. Am J Clin Oncol 2001;24(1):91-5. Abstract

Siersema PD et al. Self-expanding metal stents for complicated and recurrent esophagogastric cancer. Gastrointest Endosc 2001;54(5):579-86. Abstract

Siersema PD et al. A comparison of 3 types of covered metal stents for the palliation of patients with dysphagia caused by esophagogastric carcinoma: A prospective, randomized study. Gastrointest Endosc 2001;54(2):145-53. Abstract

Tebbutt N et al. Randomised, multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophago-gastric cancer: Interim analysis. Proc ASCO 2002; Abstract 523.

Urba SG et al. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol 2001;19(2):305-13. Abstract

Vakil N et al. A prospective, randomized, controlled trial of covered expandable metal stents in the palliation of malignant esophageal obstruction at the gastroesophageal junction. Am J Gastroenterol 2001;96(6):1791-6. Abstract

Waters JS et al. Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: Results of a randomized trial. Br J Cancer 1999;80(1-2):269-72. Abstract